---
schema_version: "secwatch.filing_event.v1"
accession: "0001663577-26-000218"
form_type: "8-K"
ticker: "BPTH"
cik: "0001133818"
company_name: "BIO-PATH HOLDINGS, INC."
filed_at: "2026-07-16T17:56:43+00:00"
generated_at: "2026-07-16T17:58:20.951197+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Bio-Path pivots to crypto treasury, signs LOI with altFINS, and engages Farrington for biotech asset sale

## Summary
- Raised $28,659 from Reg A sales of 955,300 shares; authorized 5M Series B Preferred shares convertible into 1,000 common each.
- MD Anderson agreed to restart Phase 2 AML trials if Bio-Path pays $292,264 (BP1001) and $63,287 (BP1002) past due.
- Issued 22,342 Series B Preferred for Himalaya Technologies (OTC: HMLA) valued at $670,260, making HMLA a majority-owned subsidiary.
- Engaged Farrington Capital for exclusive out-license/asset sale of DNAbilize platform and all drug programs; 60-day exclusivity.
- Signed LOI with altFINS for Gen2 digital asset treasury; altFINS to receive 2.5M BPTH shares, BPTH gets option to invest €2M at €7.4M valuation.

## SEC filing metadata
- accession: 0001663577-26-000218
- form_type: 8-K
- ticker: BPTH
- cik: 0001133818
- company_name: BIO-PATH HOLDINGS, INC.
- filed_at: 2026-07-16T17:56:43+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.02, 5.03, 7.1, 8.1
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133818/000166357726000218/0001663577-26-000218-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133818/000166357726000218/bpth_8k071626.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001663577-26-000218
- JSON: https://secwatch.observer/filing/0001663577-26-000218.json
- Plain text: https://secwatch.observer/filing/0001663577-26-000218.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.